Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18706706 | METHODS FOR PREPARING DIHYDROXYAMMONIUM 5,5'-BISTETRAZOLE-1,1'DIOLATE | May 2024 | January 2025 | Allow | 9 | 1 | 0 | No | No |
| 18583627 | SOLID FORMS OF ISOQUINOLINONES, AND PROCESS OF MAKING, COMPOSITION COMPRISING, AND METHODS OF USING THE SAME | February 2024 | April 2025 | Allow | 14 | 1 | 1 | No | No |
| 18442417 | NOVEL PROCESS FOR THE PREPARATION TAVABOROLE AND ITS INTERMEDIATES | February 2024 | February 2025 | Abandon | 12 | 1 | 1 | No | No |
| 18437702 | 4-PHENYLPIPERIDINES, THEIR PREPARATION AND USE | February 2024 | March 2025 | Allow | 13 | 1 | 0 | No | No |
| 18399861 | 2-PHENYL-3,4-DIHYDROPYRROLO[2,1 -F] [1,2,4]TRIAZINONE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | December 2023 | March 2025 | Allow | 14 | 1 | 0 | Yes | No |
| 18395979 | METHODS FOR THE SYNTHESIS OF DEUTERATED DEXTROMETHORPHAN | December 2023 | March 2025 | Allow | 14 | 1 | 0 | No | No |
| 18516560 | MODULATORS OF TNF-ALPHA ACTIVITY | November 2023 | February 2025 | Allow | 15 | 2 | 1 | No | No |
| 18511586 | UROLITHIN DERIVATIVES AND METHODS OF USE THEREOF | November 2023 | March 2025 | Allow | 16 | 1 | 1 | No | No |
| 18511627 | UROLITHIN DERIVATIVES AND METHODS OF USE THEREOF | November 2023 | March 2025 | Allow | 16 | 1 | 1 | No | No |
| 18388041 | METHODS FOR THE SYNTHESIS OF DEUTERATED DEXTROMETHORPHAN | November 2023 | December 2024 | Allow | 14 | 1 | 0 | Yes | No |
| 18497181 | SYNTHESIS OF CANTHARIDIN | October 2023 | September 2024 | Allow | 11 | 0 | 1 | No | No |
| 18384241 | 4-(4,5-BIS(4-BROMOPHENYL)-2-(4-METHOXYPHENYL)-1H-IMIDAZOL-1-YL)BUTANOIC ACID AS AN ANTIMICROBIAL COMPOUND | October 2023 | February 2024 | Allow | 3 | 1 | 0 | No | No |
| 18379125 | N'-(2-(5-PHENYL-1,3,4-OXADIAZOL-2-YLTHIO)ACETOXY)-2- NAPHTHIMIDAMIDE AS ANTIMICROBIAL COMPOUND | October 2023 | March 2024 | Allow | 5 | 1 | 0 | No | No |
| 18371282 | Lipid Disulfide Prodrugs and Uses Related Thereto | September 2023 | April 2025 | Allow | 19 | 1 | 0 | No | No |
| 18232198 | OXOPYRIDINE DERIVATIVES USEFUL AS AMINOCARBOXYMUCONATE SEMIALDEHYDE DECARBOXYLASE (ACMSD) INHIBITORS | August 2023 | June 2025 | Allow | 22 | 2 | 1 | Yes | No |
| 18228452 | COMPOSITIONS AND METHODS OF MODULATING 15-PGDH ACTIVITY | July 2023 | June 2025 | Abandon | 22 | 2 | 0 | No | No |
| 18348913 | BUTYL-BRIDGED DIPHOSPHINE LIGANDS FOR ALKOXYCARBONYLATION | July 2023 | December 2024 | Abandon | 18 | 2 | 0 | No | No |
| 18216669 | (CYANO-DIMETHYL-METHYL)-ISOXAZOLES AND -[1,3,4]THIADIAZOLES | June 2023 | February 2025 | Allow | 20 | 1 | 0 | No | No |
| 18344594 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | June 2023 | November 2024 | Abandon | 17 | 0 | 1 | No | No |
| 18313428 | PROCESSES OF MAKING AND CRYSTALLINE FORMS OF A MDM2 INHIBITOR | May 2023 | November 2024 | Abandon | 19 | 1 | 0 | No | No |
| 18296151 | CYCLOBUTYL PURINE DERIVATIVE OR SALT THEREOF | April 2023 | September 2024 | Allow | 17 | 1 | 1 | Yes | No |
| 18129857 | BISACYL DIGERMANIUM COMPOUNDS, THEIR PREPARATION AND THEIR USE AS PHOTOINITIATOR FOR RADICAL POLYMERIZATION | April 2023 | October 2024 | Abandon | 19 | 2 | 1 | No | No |
| 18175956 | CARBORANE HYDROXAMIC ACID MATRIX METALLOPROTEINASE INHIBITORS AND AGENTS FOR BORON NEUTRON CAPTURE THERAPY | February 2023 | May 2024 | Allow | 15 | 1 | 0 | No | No |
| 18153947 | BENZOTHIA(DI)AZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | January 2023 | June 2024 | Allow | 17 | 1 | 0 | Yes | No |
| 18093704 | TARGETED NITROXIDE AGENTS | January 2023 | May 2024 | Abandon | 16 | 1 | 0 | No | No |
| 18013069 | THIOBENZOPYRANS AND THEIR USE IN PREPARATION OF DRUGS FOR TREATMENT OF RHEUMATOID ARTHRITIS | December 2022 | July 2024 | Allow | 19 | 1 | 0 | Yes | No |
| 18146242 | TYK2 INHIBITORS AND USES THEREOF | December 2022 | September 2024 | Abandon | 21 | 0 | 1 | No | No |
| 18087302 | HETEROCYCLIC NMDA ANTAGONISTS | December 2022 | July 2023 | Allow | 7 | 1 | 0 | Yes | No |
| 18145315 | OXABOROLE ESTERS AND USES THEREOF | December 2022 | December 2024 | Abandon | 24 | 0 | 1 | No | No |
| 18085341 | POLYETHYLENE GLYCOL DERIVATIVE AND USE THEREOF | December 2022 | September 2024 | Allow | 21 | 2 | 1 | No | No |
| 18081715 | METHOD FOR PURIFYING ETHYLENE CARBONATE THROUGH DYNAMIC CRYSTALLIZATION | December 2022 | March 2024 | Allow | 15 | 2 | 0 | No | No |
| 18081842 | USE OF MORPHINAN DERIVATIVES FOR TREATMENT OF OPIOID DELTA RECEPTOR AGONIST-RELATED DISEASE | December 2022 | April 2024 | Allow | 16 | 1 | 0 | No | No |
| 18079790 | CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME | December 2022 | March 2025 | Allow | 27 | 2 | 1 | No | No |
| 18057020 | PROTEASOME ACTIVITY ENHANCING COMPOUNDS | November 2022 | January 2025 | Allow | 26 | 2 | 0 | Yes | No |
| 18056089 | NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE INHIBITORS AND METHODS FOR USE OF THE SAME | November 2022 | February 2024 | Allow | 15 | 0 | 1 | No | No |
| 17983051 | PREPARATION OF SUFENTANIL CITRATE AND SUFENTANIL BASE | November 2022 | March 2025 | Allow | 29 | 3 | 0 | Yes | No |
| 17974613 | TYROSINE KINASE INHIBITORS | October 2022 | February 2025 | Abandon | 27 | 2 | 1 | No | No |
| 17971804 | HOST-TARGETED PAN-RESPIRATORY ANTIVIRAL SMALL MOLECULE THERAPEUTICS | October 2022 | January 2024 | Allow | 15 | 1 | 1 | Yes | No |
| 17966227 | MYC-MAX INHIBITOR COMPOUND THERAPEUTICS FOR CANCER TREATMENT, METHODS AND USES ASSOCIATED THEREWITH | October 2022 | February 2024 | Allow | 16 | 1 | 1 | No | No |
| 17962781 | SULFONYL PIPERIDINE DERIVATIVES AND THEIR USE FOR TREATING PROKINETICIN MEDIATED DISEASES | October 2022 | March 2024 | Allow | 17 | 1 | 0 | No | No |
| 17937210 | COMPOUNDS AND METHODS FOR DETECTION OF NITRIC OXIDE | September 2022 | October 2023 | Allow | 12 | 0 | 1 | No | No |
| 17933434 | DIARYL MACROCYCLE POLYMORPH | September 2022 | August 2024 | Allow | 23 | 1 | 1 | Yes | No |
| 17907972 | METHOD FOR PREPARING NEAR-INFRARED REGION II FLUORESCENT SMALL MOLECULE | August 2022 | August 2024 | Allow | 24 | 2 | 0 | No | No |
| 17877498 | Aminosteroids for the Treatment of a PTP1B Associated Disease | July 2022 | March 2024 | Abandon | 19 | 0 | 1 | No | No |
| 17869226 | ARYLAMIDE DERIVATIVE HAVING ANTITUMOR ACTIVITY | July 2022 | December 2023 | Allow | 17 | 1 | 2 | Yes | No |
| 17863941 | 4-CARBOXAMIDO-ISOINDOLINONE DERIVATIVES AS SELECTIVE PARP-1 INHIBITORS | July 2022 | May 2023 | Allow | 10 | 1 | 0 | No | No |
| 17864133 | COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY | July 2022 | March 2024 | Abandon | 20 | 0 | 1 | No | No |
| 17861567 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | July 2022 | October 2024 | Abandon | 27 | 1 | 1 | No | No |
| 17853755 | HETEROCYCLIC GLP-1 AGONISTS | June 2022 | November 2023 | Allow | 17 | 1 | 0 | No | No |
| 17737580 | SSAO INHIBITORS AND USE THEREOF | May 2022 | January 2024 | Allow | 21 | 1 | 1 | No | No |
| 17730438 | SUBSTITUTED BENZOFURAN, BENZOPYRROLE, BENZOTHIOPHENE, AND STRUCTURALLY RELATED COMPLEMENT INHIBITORS | April 2022 | August 2023 | Allow | 16 | 1 | 1 | No | No |
| 17730463 | SUBSTITUTED BENZOFURAN, BENZOPYRROLE, BENZOTHIOPHENE, AND STRUCTURALLY RELATED COMPLEMENT INHIBITORS | April 2022 | February 2024 | Allow | 22 | 2 | 0 | No | No |
| 17726807 | MODULATORS OF THE BETA-3 ADRENERGIC RECEPTOR USEFUL FOR THE TREATMENT OR PREVENTION OF HEART FAILURE AND DISORDERS RELATED THERETO | April 2022 | January 2024 | Allow | 21 | 1 | 1 | No | No |
| 17720229 | TRYPTAMINE ANALOGUES | April 2022 | February 2024 | Abandon | 22 | 3 | 1 | Yes | No |
| 17702597 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP-1) INHIBITORS AND USES THEREOF | March 2022 | December 2023 | Abandon | 21 | 0 | 1 | No | No |
| 17655630 | PYRANOPYRAZOLE AND PYRAZOLOPYRIDINE IMMUNOMODULATORS FOR TREATMENT OF AUTOIMMUNE DISEASES | March 2022 | August 2023 | Abandon | 17 | 0 | 1 | No | No |
| 17697981 | THIOPHENE DERIVATIVES AS ANTIVIRAL AGENTS | March 2022 | June 2023 | Allow | 15 | 1 | 1 | Yes | No |
| 17687654 | NOVEL ANTI-OXIDANT COMPOUNDS AND COMPOSITIONS | March 2022 | September 2023 | Abandon | 19 | 1 | 1 | No | No |
| 17685709 | DOPAMINE D3 RECEPTOR SELECTIVE ANTAGONISTS/PARTIAL AGONISTS; METHOD OF MAKING; AND USE THEREOF | March 2022 | July 2024 | Allow | 29 | 3 | 1 | Yes | No |
| 17665104 | DERIVATIVES OF RESIQUIMOD | February 2022 | April 2024 | Allow | 27 | 2 | 0 | No | No |
| 17592422 | LACTAMS AS CBL-B INHIBITORS | February 2022 | November 2024 | Abandon | 34 | 2 | 1 | No | No |
| 17649744 | GPR84 ANTAGONISTS AND USES THEREOF | February 2022 | February 2025 | Allow | 37 | 4 | 1 | Yes | No |
| 17586294 | UROLITHIN DERIVATIVES AND METHODS OF USE THEREOF | January 2022 | August 2023 | Allow | 18 | 2 | 1 | Yes | No |
| 17582150 | IMIDAZOQUINOLINE DERIVATIVES AND THEIR USE IN THERAPY | January 2022 | March 2024 | Abandon | 26 | 2 | 1 | No | No |
| 17582176 | IMIDAZOQUINOLINE DERIVATIVES AND THEIR USE IN THERAPY | January 2022 | March 2024 | Abandon | 25 | 1 | 1 | No | No |
| 17578309 | SOLID FORMS OF ISOQUINOLINONES, AND PROCESS OF MAKING, COMPOSITION COMPRISING, AND METHODS OF USING THE SAME | January 2022 | October 2023 | Allow | 21 | 1 | 1 | No | No |
| 17568824 | Aza (Indole)-, Benzothiophene-, And Benzofuran-3-Sulfonamides | January 2022 | June 2023 | Allow | 17 | 1 | 1 | No | No |
| 17624134 | BENZOTHIOPHENE, THIENOPYRIDINE AND THIENOPYRIMIDINE DERIVATIVES FOR THE MODULATION OF STING | December 2021 | March 2025 | Allow | 39 | 0 | 1 | Yes | No |
| 17560997 | COMPOSITIONS AND METHODS RELATED TO DI-SUBSTITUTED BICYCLO[2.2.1] HEPTANAMINE-CONTAINING COMPOUNDS | December 2021 | July 2023 | Allow | 19 | 1 | 1 | No | No |
| 17559051 | 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | December 2021 | March 2024 | Allow | 27 | 2 | 1 | Yes | No |
| 17556700 | RNA VIRUS INHIBITOR COMPOUNDS AND USES THEREOF | December 2021 | July 2023 | Abandon | 19 | 1 | 0 | No | No |
| 17554284 | CDK Inhibitors And Their Use As Pharmaceuticals | December 2021 | June 2024 | Allow | 30 | 2 | 1 | Yes | No |
| 17547254 | PREPARATION METHOD OF RACEMIC NICOTINE | December 2021 | January 2025 | Allow | 37 | 0 | 0 | No | No |
| 17547983 | 2-PHENYL-3,4-DIHYDROPYRROLO[2,1 -F] [1,2,4]TRIAZINONE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | December 2021 | September 2023 | Allow | 22 | 1 | 1 | No | No |
| 17596341 | METHODS FOR PREPARING CANNABINOIDS BY BASE-PROMOTED DOUBLE-BOND MIGRATION | December 2021 | June 2025 | Abandon | 42 | 0 | 1 | No | No |
| 17616748 | BIARYL DIALKYL PHOSPHINE OXIDE FPR2 AGONISTS | December 2021 | February 2025 | Abandon | 38 | 1 | 1 | No | No |
| 17614473 | SYNTHESIS METHOD FOR 1-METHYL-1H-INDAZOLE-6-CARBOXYLIC ACID | November 2021 | December 2024 | Allow | 37 | 1 | 0 | No | No |
| 17612302 | PYRIDINIUM SALT AND PEST CONTROL AGENT | November 2021 | May 2025 | Abandon | 42 | 0 | 1 | No | No |
| 17612127 | ORGANIC TRANSISTOR MATERIAL AND ORGANIC TRANSISTOR | November 2021 | May 2025 | Allow | 42 | 1 | 1 | No | No |
| 17521155 | FLUOROLACTONE AND METHOD FOR PRODUCING SAME | November 2021 | May 2024 | Allow | 30 | 2 | 1 | No | No |
| 17520287 | CARDIOPATHY-REDUCING PHOSPHODIESTER LIPIDS | November 2021 | April 2023 | Allow | 17 | 1 | 1 | No | No |
| 17452928 | METHODS OF MANUFACTURING OF NIRAPARIB | October 2021 | November 2022 | Allow | 13 | 0 | 0 | No | No |
| 17506331 | Aza (Indole)-, Benzothiophene-, And Benzofuran-3-Sulfonamides | October 2021 | April 2023 | Allow | 18 | 2 | 0 | No | No |
| 17505745 | PYRAZOLE AMINE REACTIVE CRYSTALLIZATION | October 2021 | July 2023 | Allow | 21 | 1 | 0 | No | No |
| 17603536 | METHOD FOR PRODUCING CIS-(-)-FLOCINO PIPERIDOL | October 2021 | January 2025 | Allow | 40 | 3 | 0 | No | No |
| 17500039 | PROCESSES OF MAKING AND CRYSTALLINE FORMS OF A MDM2 INHIBITOR | October 2021 | June 2023 | Abandon | 20 | 1 | 0 | No | No |
| 17593643 | INDOLE ALKALOID COMPOUND IN NONI ENZYME AND PREPARATION METHOD AND APPLICATION THEREOF | September 2021 | February 2025 | Allow | 40 | 1 | 1 | No | No |
| 17441287 | METHOD FOR SYNTHESIZING LACTAM DERIVATIVES WITHOUT USE OF CATALYST | September 2021 | September 2023 | Allow | 24 | 1 | 1 | No | No |
| 17479838 | PROCESS FOR PREPARING 5-[[4-[2-[5-(1-HYDROXYETHYL)-2-PYRIDINYL]ETHOXY]PHENYL]-METHYL]-2,4-THIAZOLIDINEDIONE AND SALTS THEREOF | September 2021 | March 2023 | Allow | 18 | 1 | 0 | No | No |
| 17476028 | COMPOUNDS AS NEUROKININ-1 RECEPTOR ANTAGONISTS AND USES THEREOF | September 2021 | September 2023 | Allow | 24 | 1 | 0 | No | No |
| 17473032 | L-Dopa Enhanced with a Neuroprotective Agent as a Therapy for Parkinson's Disease | September 2021 | July 2023 | Abandon | 22 | 1 | 1 | No | No |
| 17435606 | SYNTHESIS OF 4-AMINO-5-METHYL-1H-PYRIDIN-2(1H)-ON (INTERMEDIATE COMPOUND FOR THE SYNTHESIS OF THE MR ANTAGONIST FINERENONE) FROM 2-CHLORO-5-METHYL-4-NITRO-PYRIDINE-1-OXIDE USING THE INTERMEDIATE COMPOUND 2-CHLORO-5-METHYL-4-PYRIDINAMINE | September 2021 | March 2025 | Allow | 43 | 1 | 0 | No | No |
| 17434004 | COMPOUND | August 2021 | August 2023 | Abandon | 24 | 0 | 1 | No | No |
| 17407278 | METHODS OF PREPARATION OF AMINOBORANES AND APPLICATIONS FOR BORYLATION AND SUZUKI COUPLING | August 2021 | April 2024 | Abandon | 32 | 2 | 1 | No | No |
| 17401892 | PROCESS FOR THE PREPARATION OF 6-(2-HYDROXY-2-METHYLPROPOXY)-4-(6-(6-((6-METHOXYPYRIDIN-3-YL)METHYL)-3,6-DIAZABICYCLO[3.1.1]HEPTAN-3-YL)PYRIDIN-3-YL)PYRAZOLO[1,5-A]PYRIDINE-3-CARBONITRILE | August 2021 | July 2023 | Allow | 23 | 1 | 0 | No | No |
| 17400772 | METHODS AND SYSTEMS FOR PRODUCTION OF FURFURAL | August 2021 | July 2025 | Abandon | 47 | 2 | 0 | Yes | Yes |
| 17430426 | HERBICIDAL COMPOSITIONS | August 2021 | January 2025 | Abandon | 41 | 0 | 1 | No | No |
| 17398257 | FLUOROLACTONE AND METHOD FOR PRODUCING SAME | August 2021 | June 2025 | Allow | 46 | 4 | 1 | Yes | No |
| 17398155 | NOVEL (CYANO-DIMETHYL-METHYL)-ISOXAZOLES AND -[1,3,4]THIADIAZOLES | August 2021 | March 2023 | Allow | 20 | 1 | 0 | No | No |
| 17390497 | Compounds for Treating Tauopathies and Restless Leg Syndrome and Methods of Using and Screening for Same | July 2021 | May 2024 | Abandon | 34 | 2 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner O DELL, DAVID K.
With a 22.2% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 40.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is above the USPTO average, suggesting that filing an appeal can be an effective strategy for prompting reconsideration.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
Examiner O DELL, DAVID K works in Art Unit 1621 and has examined 353 patent applications in our dataset. With an allowance rate of 82.4%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 30 months.
Examiner O DELL, DAVID K's allowance rate of 82.4% places them in the 48% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.
On average, applications examined by O DELL, DAVID K receive 1.72 office actions before reaching final disposition. This places the examiner in the 50% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by O DELL, DAVID K is 30 months. This places the examiner in the 39% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +16.2% benefit to allowance rate for applications examined by O DELL, DAVID K. This interview benefit is in the 60% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.
When applicants file an RCE with this examiner, 29.2% of applications are subsequently allowed. This success rate is in the 45% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 56.4% of cases where such amendments are filed. This entry rate is in the 78% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants request a pre-appeal conference (PAC) with this examiner, 40.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 34% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.
This examiner withdraws rejections or reopens prosecution in 70.0% of appeals filed. This is in the 51% percentile among all examiners. Of these withdrawals, 66.7% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.
When applicants file petitions regarding this examiner's actions, 49.0% are granted (fully or in part). This grant rate is in the 58% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 9.9% of allowed cases (in the 96% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 5.5% of allowed cases (in the 80% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.